Summary

The benefit of oral anticoagulation following acute coronary syndrome (ACS) has been demonstrated in warfarin trials, showing significant reductions in myocardial infarction and stroke at the expense of an increased risk of bleeding. The impact of oral direct thrombin inhibitors and direct factor Xa inhibitors in ACS patients has been the subject of several clinical trials.